Showing results (171-180 of 379) with videos related to
Sort By:
Pageof 38
Frontiers in Immunology|May 29, 2024
Case report: Durable complete response of a mucosal melanoma of the rectum after neoadjuvant immunotherapy with ipilimumab plus nivolumabOskar Krueger, Robin Eisenburger, Alpaslan Tasdogan, et al.Journal Der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG|January 22, 2026
Complete lymph node dissection versus selective lymph node extirpation in melanoma patients with nodal macrometastasis and adjuvant systemic therapyKristine E Mayer, Jessica C Hassel, Jannik Sambale, et al.Annals of the Rheumatic Diseases|April 1, 2024
Altered serum metabolome as an indicator of paraneoplasia or concomitant cancer in patients with rheumatic diseaseKarolina Gente, Manuel Feisst, Dorothea Marx, et al.European Journal of Cancer (Oxford, England : 1990)|March 29, 2026
Diagnostic and prognostic parameters for immune checkpoint inhibitor-related myocarditis: A meta-analysisTobias Lerchner, Florian Buehning, Julia Vogel, et al.The Journal of Investigative Dermatology|July 17, 2024
Tebentafusp Induces a T-Cell-Driven Rash in Melanocyte-Bearing Skin as an Adverse Event Consistent with the Mechanism of ActionJessica C Hassel, Sarah Stanhope, Alexander Greenshields-Watson, et al.European Journal of Cancer (Oxford, England : 1990)|March 11, 2021
Hematological immune related adverse events after treatment with immune checkpoint inhibitorsRafaela Kramer, Anne Zaremba, Alvaro Moreira, et al.European Journal of Cancer (Oxford, England : 1990)|March 13, 2022
Genetic characterization of advanced conjunctival melanoma and response to systemic treatmentGeorg C Lodde, Philipp Jansen, Inga Möller, et al.Cancers|February 27, 2026
COMBI-EU: Real-World Evidence on Adverse Event Management and Time on Therapy with Adjuvant Dabrafenib Plus Trametinib in Patients with BRAF V600-Mutant MelanomaMichael Weichenthal, Dirk Debus, Lisa Zimmer, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 4, 2013
Incidence of new primary melanomas after diagnosis of stage III and IV melanomaLisa Zimmer, Lauren E Haydu, Alexander M Menzies, et al.Cancer Immunology, Immunotherapy : CII|May 1, 2020
Deep abscopal response to radiotherapy and anti-PD-1 in an oligometastatic melanoma patient with unfavorable pretreatment immune signatureTsubasa Watanabe, Elke Firat, Jutta Scholber, et al.Pageof 38